![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
This retrospective study evaluated the secondary clinical risk score at relapse, the prognostic significance of pre-transplant positron emission tomography (PET), and complete remission (CR) assessed by computed tomography (CT) after salvage chemotherapy before autologous stem cell transplant (ASCT) in 76 patients with relapsed/refractory Hodgkin lymphoma (HL). Median follow-up after ASCT was 23 months. Overall 11/20 PET-positive and 14/56 PET-negative patients relapsed after ASCT. In univariate analysis, only PET negativity before ASCT was significantly associated with better 2-year progression-free survival (PFS) (72.7 ± 6.3% vs. 36.1 ± 11.6%, p = 0.01) and 2-year overall survival (OS) (90.3 ± 4.1% vs. 61.4 ± 11.6%, p = 0.009). Other factors were not significant. In multivariate analysis, none of the evaluated factors were significant for PFS and OS. However, positive pre-transplant PET identified a population with worse PFS and OS at least in univariate analysis.
Acknowledgements
Nuclear medicine specialists were: Otakar Belohlavek, PET center, Na Homolce Hospital, Prague, Czech Republic; Karol Bolcak, Department of Nuclear Medicine and Positron Emission Tomography, Masaryk Institute of Oncology, Brno, Czech Republic; Jiri Ferda, Clinic of Imaging Methods, Charles University Hospital, Pilsen, Czech Republic.
Biostatisticians were: Karel Chroust, Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic; Bohumir Prochazka, National Institute of Public Health, Prague, Czech Republic.
This work was supported by the grant from Ministry of School and Education MSM 0021620808.
Potential conflict of interest:
Disclosure forms provided by the authors are available with the full text of this article at www.informahealthcare.com/lal.